Chemed Corporation Reports Strong Q3 2026 Growth Driven by VITAS Segment
Chemed Corporation (CHE) reported robust third-quarter 2026 financial results, highlighted by a 10.6% increase in consolidated revenue to $690.9 million and a 28.1% surge in adjusted diluted EPS to $6.75. The growth was primarily propelled by the VITAS Healthcare segment, which saw a 12.2% rise in net patient revenue due to increased days of care and improved reimbursement rates. While VITAS showed strong margin expansion, the Roto-Rooter segment faced headwinds including rising fuel costs and higher customer acquisition expenses. Despite these pressures, Roto-Rooter achieved 5.5% same-store revenue growth. Management remains optimistic, expecting to meet or slightly exceed the high end of their previously issued adjusted EPS guidance for the fiscal year.
Tickers: $CHE
Topics: acquisitions EBITDA EPS beat revenue growth segment performance